FrançaisAre analysts right about BioMarin Pharmaceutical (BMRN)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For BioMarin Pharmaceutical, we replayed every analyst price target of the past 12 months and measured the real outcome: 18% were profitable, average return -1% (216 calls). At 3 months: +1% average return (42% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Morgan Stanley | 17 | 12% | -2% |
| Credit Suisse | 17 | 35% | +17% |
| Stifel | 15 | 27% | -3% |
| Cantor Fitzgerald | 15 | 0% | -19% |
| Barclays | 12 | 17% | -3% |
Valuation
Is BioMarin Pharmaceutical overvalued, and is it a good time to buy BioMarin Pharmaceutical right now? If you're wondering, here's a recap to make up your own mind: BioMarin Pharmaceutical's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price ÷ earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects — but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | BioMarin Pharmaceutical | Sector median (Health Care) |
|---|---|---|
| P/E | 176.5 | 29.4 |
| Forward P/E | 10.1 | 17.1 |
| Net margin | 2% | 12% |
👉 BioMarin Pharmaceutical trades above its sector median (176.5 vs 29.4) — the market expects higher growth; watch out for disappointment.
📖 P/E, PEG, margin…: see the glossary
Frequently asked questions
Is BioMarin Pharmaceutical a buy right now?
The analyst consensus on BioMarin Pharmaceutical (BMRN) is "Buy" (33 bullish, 0 bearish calls over 12 months). This is not advice: historically, 18% of their targets on this stock turned out profitable over 1 year.
What is BioMarin Pharmaceutical's price target?
The median 12-month price target is $97.00 (+49% vs $65.29), ranging from $59.00 to $124 (13 analysts).
Are analysts accurate on BioMarin Pharmaceutical?
Over 1 year, 18% of analyst targets on BioMarin Pharmaceutical were profitable, for an average return of -1% (across 216 timestamped calls). This is JPI Invest's accuracy metric.
What is the BioMarin Pharmaceutical stock forecast?
Analysts target a median of $97.00 within 12 months, i.e. +49% vs the current price. The most bullish targets $124, the most cautious $59.00.
What is the BioMarin Pharmaceutical stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $97.00, +49%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (18%), and the stock's past trajectory.
Is BioMarin Pharmaceutical overvalued?
Its P/E is 176.5, forward P/E 10.1. A forward P/E lower than the current P/E means earnings are expected to grow.
📊 See the full interactive analysis of BioMarin Pharmaceutical →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.